143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study

Background

Atezo SC (with recombinant human hyaluronidase) is approved in the EU and US in the same indications as atezo IV based on IMscin001 (NCT03735121) data. IMscin002 (NCT05171777) data show that most pts (70.7%; n=87/123) prefer atezo SC vs IV. We present exploratory analyses on this preference and its strength, for different pt subgroups from IMscin002.

Methods

Eligible pts ≥18 years old with EGFR/ALK wild-type tumors had PD-L1+ resected NSCLC (Stage II, IIIA or selected IIIB; AJCC 8^th ed) with prior chemotherapy and no evidence of recurrence, or untreated PD-L1-high Stage IV NSCLC. Pts were randomized 1:1 to receive atezo SC or atezo IV for 3 weeks, and switched to the alternative formulation after Cycle 3. Primary endpoint: pt preference for atezo SC or IV (or no preference), evaluated at Cycle 6 or after ≥2 consecutive administrations of each formulation in pts who discontinued before Cycle 6, via pt preference questionnaires (Question 1: preference for one formulation [or no preference]; Question 2 [exploratory analysis]: strength of preference for this formulation).

Results

At data cutoff (9 Nov 2023), 123 evaluable pts answered Question 1 (atezo SC preferred: n=87; atezo IV preferred: n=26; no preference: n=10). Of the pts who also indicated their strength of preference for atezo SC (n=87) or IV (n=25), 35.6% had a very strong preference, 50.6% had a fairly strong preference and 13.8% had a not very strong preference for atezo SC; vs 28.0%, 44.0% and 28.0% for atezo IV, respectively. Preference for atezo SC or IV in different pt subgroups is shown in the Table. These data were generally consistent with those seen in the overall population, except for pts >74 years old who showed a stronger preference for atezo SC vs IV. Table: 143P

Data shown as a % of the total number of evaluable pts who answered Questions 1 and 2 (n=123) Strength of preference missing for 1 pt who preferred atezo IV: *4.2%; †2.6%; ^‡1.6%; ^§1.3%; ^¶2.9%

Conclusions

Pts showed higher preference for atezo SC vs IV irrespective of their baseline/disease characteristics or injection administration times. A stronger preference for atezo SC vs IV was shown in older pts.

Clinical trial identification

NCT05171777.

Editorial acknowledgement

This study is sponsored by F. Hoffmann-La Roche Ltd. Third party medical writing assistance, under the direction of the authors, was provided by Lietta Nicolaides, PhD of Ashfield MedComms, an Inizio company, and was funded by F. Hoffmann-La Roche Ltd.

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.

Funding

F. Hoffmann-La Roche Ltd.

Disclosure

M. Majem Tarruella: Financial Interests, Personal, Advisory Role, Consulting or Advisory Role: Merck Sharp & Dohme, Pfizer, Boehringer Ingelheim, Novartis, Helsinn Therapeutics, Takeda, Sanofi, Janssen Oncology, Pierre Fabre, Bristol Myers Squibb, AstraZeneca, Roche; Non-Financial Interests, Personal, Invited Speaker: Roche, Merck Sharp & Dohme, Pfizer, AstraZeneca, Helsinn Therapeutics; Financial Interests, Personal, Other, Travel, Accommodations and Expenses: AstraZeneca, Roche, MSD Oncology; Financial Interests, Personal, Research Funding: Bristol Myers Squibb, Roche, AstraZeneca; Financial Interests, Institutional, Research Grant: Roche, AstraZeneca . Z. Zvirbule: Financial Interests, Personal and Institutional, Advisory Board: GSK, AstraZeneca, Roche, MSD; Financial Interests, Personal and Institutional, Invited Speaker: MSD; Financial Interests, Personal and Institutional, Principal Investigator: Merck Sharp & Dohme Latvija, Roche, Genentech, Shanghai Henlius Biotech. E.P. Korbenfeld: Financial Interests, Personal, Advisory Board: BMS, AstraZeneca, MSD, Pfizer, Knight; Financial Interests, Personal, Other, Honoraria: AstraZeneca; Financial Interests, Personal, Principal Investigator: Centro Oncologico; Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD. J. Kolb-Sielecki: Financial Interests, Personal and Institutional, Local PI: Warmian-Masurian Center of Pulmonary Diseases. L.A. Herraez Baranda: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks or ownership: F. Hoffmann-La Roche Ltd. A.Y. Castro Sanchez: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd. A. Bustillos: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd. L.X. Liu: Financial Interests, Personal, Full or part-time Employment: Genentech, Inc. F. Cappuzzo: Non-Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati, Galecto, OSE, Illumina, ThermoFisher, MSD; Non-Financial Interests, Personal, Advisory Role: Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati, Galecto, OSE, Illumina, ThermoFisher, MSD; Non-Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, PharmaMar, Novocure, Mirati, Galecto, OSE, Illumina, ThermoFisher, MSD.